Skincoach is a mobile solution designed to help patients manage skin reactions commonly associated with EGFRi treatments.

How it works

Request a skin checkup from a qualified dermatologist at any time.

Watch videos on what to expect from your treatment, and simple recommendations on how to look after your skin.

Generate automatic reports for your physician.

 

Skincoach is only available to patients who have been referred by their physician, and requires an ‘unlock code’ provided by a Doctor.

About Skincoach

Skincoach has been developed in a partnership between Amgen and LEO Innovation Lab.

Our Advisors
John Zibert John Zibert Chief Medical Officer

Dr John Zibert is the Medical Director at LEO Innovation Lab, creating new solutions for the benefit of patients with the goal of achieving healthy skin anytime and anywhere. He holds a PhD in medicine, MSc in Human biology and BSc in Microbiology from University of Copenhagen, Denmark and University of Otago, New Zealand. He has been carrying out clinical research on skin diseases and cancer for over a decade.

Pilar García-Muret Pilar García-Muret Dermatologist

Dra Ma Pilar García-Muret is Associate Professor at the Universitat Autònoma de Barcelona, and a practicing dermatologist at the Hospital de la Santa Creu i Sant Pau, specialising in cutaneous oncology, cutaneous toxic reactions and general dermatology. The Hospital de la Santa Creu i Sant Pau operate the ProADO program, a pioneering educational and preventative program for cancer patients.

 
Important Information

Skincoach including all Content provided in Skincoach is provided for informational purposes only. All information given is based on expert advice. Skincoach does not constitute, and is not intended to be a substitute for, professional medical advice, medical diagnosis or treatment provided by a healthcare professional.

Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition and any additional treatment. The information provided by Skincoach does not replace the opinion of your healthcare professional. Never disregard professional medical advice or delay in seeking it because of something you may have read or done on Skincoach.

Skincoach should not be considered, a medical device delivering medical diagnosis or treatment recommendation, or as a substitute to an in-person consultation with a dermatologist. The images used by dermatologists to evaluate skin conditions are not of medical quality and cannot support a medical decision in itself. The information provided is not dependent on calculations performed by the Skincoach platform or any image processing; all information, following a simple indexation, is reviewed manually by dermatologists.

Skincoach and entities or persons associated with Skincoach are not responsible or liable for any health needs, or damages, as a result of using this application.

 
References

Barton-Burke M, Ciccolini K, Mekas M, Burke S. Dermatologic Reactions to Targeted Therapy. Nursing Clinics of North America. 2017. 52(1): 83-113.

Hofheinz RD, Deplanque G, Komatsu Y, Kobayashi Y, Ocvirk J, Racca P, Guenther S, Zhang J, Lacouture ME, Jatoi A. Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. Oncologist. 2016 Dec;21(12):1483-1491.

Hofheinz RD, Segaert S, Safont MJ, Demony G, Prenen H. Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors. Critical reviews in Oncology / Hematology. 2017 114 102-113.

Tischer B, Huber R, Kraemer M, Lacouture ME. Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Support Care Cancer. 2017. October, 25:651-660.

Stanculeanu DL, Zob D, Toma OC, Georgescu B, Papagheorghe L, Mihaila RI. Cutuaneous Toxicities of Molecular Targeted Therapies. Maedica - a Journal of Clinical Medicine. 2017. 12(1): 48:54.